Ashley A Vo1, Aditi Sinha, Mark Haas, Jua Choi, James Mirocha, Joseph Kahwaji, Alice Peng, Rafael Villicana, Stanley C Jordan. 1. 1 Kidney Transplant Program and Transplant Immunology, Cedars-Sinai Medical Center, Los Angeles, CA. 2 Division of Pediatric Nephrology, All India Institute of Medical Sciences, New Delhi, India. 3 Department of Pathology, Cedars-Sinai Medical Center, Los Angeles, CA. 4 Biostatistics Core, Cedars-Sinai Medical Center, Los Angeles, CA.
Abstract
BACKGROUND: Desensitization with intravenous immunoglobulin and rituximab (I+R) significantly improves transplant rates in highly sensitized patients, but antibody-mediated rejection (ABMR) remains a concern. PATIENTS AND METHODS: Between July 2006 and December 2012, 226 highly sensitized patients received transplants after desensitization. Most received alemtuzumab induction and standard immunosuppression. Two groups were examined: ABMR (n = 181) and ABMR (n = 45, 20%). Risk factors for ABMR, pathology, and outcomes were assessed. RESULTS: Significant risks for ABMR included previous transplants and pregnancies as sensitizing events, donor-specific antibody (DSA) relative intensity scores greater than 17, presence of both class I and II DSAs at transplant and time on waitlist. The ABMR showed a significant benefit for graft survival and glomerular filtration rate at 5 years (P < 0.0001). Banff pathology characteristics for ABMR patients with or without graft loss did not differ. C4d versus C4d ABMR did not predict graft loss (P = 0.086). Thrombotic microangiopathy (TMA) significantly predicted graft failure (P = 0.045). The ABMR episodes were treated with I+R (n = 25), or, in more severe ABMR, plasma exchange (PLEX)+I+R (n = 20). Graft survival for patients treated with I+R was superior (P = 0.028). Increased mortality was seen in ABMR patients experiencing graft loss after ABMR treatment (P = 0.004). The PLEX + Eculizumab improved graft survival for TMA patients (P = 0.036). CONCLUSION: Patients desensitized with I+R who remain ABMR have long-term graft and patient survival. The ABMR patients have significantly reduced graft survival and glomerular filtration rate at 5 years, especially TMA. Severe ABMR episodes benefit from treatment with PLEX + Eculizumab. The DSA-relative intensity scores at transplant was a strong predictor of ABMR. Donor-specific antibody avoidance and reduction strategies before transplantation are critical to avoiding ABMR and improving long-term outcomes.
BACKGROUND: Desensitization with intravenous immunoglobulin and rituximab (I+R) significantly improves transplant rates in highly sensitized patients, but antibody-mediated rejection (ABMR) remains a concern. PATIENTS AND METHODS: Between July 2006 and December 2012, 226 highly sensitized patients received transplants after desensitization. Most received alemtuzumab induction and standard immunosuppression. Two groups were examined: ABMR (n = 181) and ABMR (n = 45, 20%). Risk factors for ABMR, pathology, and outcomes were assessed. RESULTS: Significant risks for ABMR included previous transplants and pregnancies as sensitizing events, donor-specific antibody (DSA) relative intensity scores greater than 17, presence of both class I and II DSAs at transplant and time on waitlist. The ABMR showed a significant benefit for graft survival and glomerular filtration rate at 5 years (P < 0.0001). Banff pathology characteristics for ABMR patients with or without graft loss did not differ. C4d versus C4d ABMR did not predict graft loss (P = 0.086). Thrombotic microangiopathy (TMA) significantly predicted graft failure (P = 0.045). The ABMR episodes were treated with I+R (n = 25), or, in more severe ABMR, plasma exchange (PLEX)+I+R (n = 20). Graft survival for patients treated with I+R was superior (P = 0.028). Increased mortality was seen in ABMR patients experiencing graft loss after ABMR treatment (P = 0.004). The PLEX + Eculizumab improved graft survival for TMApatients (P = 0.036). CONCLUSION:Patients desensitized with I+R who remain ABMR have long-term graft and patient survival. The ABMR patients have significantly reduced graft survival and glomerular filtration rate at 5 years, especially TMA. Severe ABMR episodes benefit from treatment with PLEX + Eculizumab. The DSA-relative intensity scores at transplant was a strong predictor of ABMR. Donor-specific antibody avoidance and reduction strategies before transplantation are critical to avoiding ABMR and improving long-term outcomes.
Authors: Robin Schmitz; Zachary W Fitch; Paul M Schroder; Ashley Y Choi; Annette M Jackson; Stuart J Knechtle; Jean Kwun Journal: Transpl Int Date: 2020-01 Impact factor: 3.782
Authors: J S Young; J Chen; M L Miller; V Vu; C Tian; J J Moon; M-L Alegre; R Sciammas; A S Chong Journal: Am J Transplant Date: 2016-04-04 Impact factor: 8.086
Authors: Jean Kwun; Christopher Burghuber; Miriam Manook; Brian Ezekian; Jaeberm Park; Janghoon Yoon; John S Yi; Neal Iwakoshi; Adriana Gibby; Jung Joo Hong; Alton B Farris; Allan D Kirk; Stuart J Knechtle Journal: Blood Adv Date: 2017-10-26
Authors: Irene K Kim; Jua Choi; Ashley A Vo; Alexis Kang; Mitasha Patel; Mieko Toyoda; James Mirocha; Elaine S Kamil; J Louis Cohen; Sabrina Louie; Odette Galera; Stanley C Jordan; Dechu P Puliyanda Journal: Transplantation Date: 2017-04 Impact factor: 4.939
Authors: C K Burghuber; J Kwun; E J Page; M Manook; A C Gibby; F V Leopardi; M Song; A B Farris; J J Hong; F Villinger; A B Adams; N N Iwakoshi; S J Knechtle Journal: Am J Transplant Date: 2016-03-25 Impact factor: 8.086